CYTEA BIO
Lionel Brodard is a seasoned finance professional with extensive experience in the biotech sector. Currently serving as the Chief Financial Officer at CYTEA|BIO, a pre-clinical stage biotech company, and MedXCell, a Swiss/French biotech venture builder, Lionel also holds the position of Finance Manager at SOLARSPLIT, a platform aimed at simplifying solar energy investment. As a co-founder of HelveticApp, which focuses on IT and multimedia solutions, Lionel has previous experience in academic settings as a Teaching Assistant at HEC Lausanne and as a part-time Clinical Trial Coordinator at Celgene. Educational qualifications include a Master of Science in Financial Engineering from EPFL and a Bachelor of Science in Economics from HEC Lausanne, complemented by a CAS in the Management of Biotech, Medtech & Pharma Ventures.
This person is not in any teams
This person is not in any offices
CYTEA BIO
CYTEA BIO is a pre-clinical stage biotech company developing therapeutic products by combining genetically unmodified effector cells and engineered targeting ligands. Its patented Pin™ Platform enables practically limitless combinations of effector mechanisms and targeting ligands for applications in oncology and immunology. CYTEA BIO is the first portfolio company of MedXCell, a European cell therapy venture builder with offices in Switzerland, France and the US. MedXCell focuses on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders, with the aim to turn promising academic ideas into commercially viable propositions.